Prof. Qingyuan Zhang 张清媛
Chief Physician, Professor
Department of Medical Oncology (II), Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and biological therapy for malignant tumors, with a focus on breast cancer and lymphoma. Expertise includes reversing drug resistance, anti-angiogenic therapy, and standardized, individualized treatment for refractory cancers.
Dr. Zhang is a Chief Physician and Professor at Harbin Medical University Cancer Hospital, serving as Vice President. Dr. Zhang holds degrees from Harbin Medical University and trained at the University of Calgary Cancer Centre in Canada. Research focuses on tumor immunology and biology, with multiple national grants and publications.
Professional roles
- Vice Chair, Lymphoma Professional Committee, China Anti-Cancer Association
- Vice Chair, Rehabilitation and Palliative Care Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Chinese Society of Clinical Oncology (CSCO)
- Chair, Lymphoma Professional Committee, Heilongjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Qingyuan). Papers usually list the name as Qingyuan Zhang or Zhang Q.
Selected publications
199 papers on PubMed matched by name and affiliation; 67 as first or senior author since 2016. Most recent first- or senior-author papers:
- Target Oncol, 2026 (senior author): Imlunestrant as Monotherapy or in Combination with Abemaciclib in ER+, HER2- Advanced Breast Cancer: Chinese Subgroup Analysis of the Phase III Randomized EMBER-3 Study. PubMed 43002362
- Immunology, 2026 (senior author): HMGB1-Induced Metabolic Rewiring of Macrophages via RAGE/MAPK Fosters Endocrine Resistance in Breast Cancer. PubMed 42527048
- Biochem Pharmacol, 2026 (senior author): EFO2 promotes triple-negative breast cancer progression and reduces CD8(+) T cell-mediated killing by acetylating USF1 to enhance SLC2A1-mediated glycolysis. PubMed 42456828
- Biomol Biomed, 2026 (senior author): Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial. PubMed 42483812
- Br J Cancer, 2026 (senior author): Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer. PubMed 41366063
- Int Immunopharmacol, 2025 (senior author): SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer. PubMed 40976049
- Int Immunopharmacol, 2025 (senior author): Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3. PubMed 40614603
- Eur J Pharmacol, 2025 (senior author): Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity. PubMed 39892447
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion